{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:11:44Z","timestamp":1787184704838,"version":"build-2736575974"},"reference-count":90,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Iacocca Foundation","award":["001-20"],"award-info":[{"award-number":["001-20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The three pathological hallmarks of multiple sclerosis (MS) are inflammation, demyelination, and progressive neurodegeneration. None of the approved disease-modifying therapies for MS counters all three pathologies, and, more specifically, none is approved for neuroprotection. Axonal loss is the most significant contributor to chronic and irreversible disability in MS. A tantalizing molecular target has emerged to uniquely counter all three MS pathologies: tumor necrosis factor receptor 2 (TNFR2). Agonism or activation of TNFR2 has been shown in MS models to induce immunosuppression, oligodendrocyte precursor differentiation, and neuroprotection. Further, in basic science studies stemming from the past 15 years, TNFR2 agonism is known to be a strong inducer of T-regulatory cells (Tregs). Treg cells, and especially those expressing TNFR2, are known to confer the strongest suppression per cell type. TNFR2 is even more attractive as a therapeutic target because of its restricted expression by only a handful of CNS and immune cell subsets, thereby minimizing the likelihood of systemic and other adverse effects. Recent antibody design work suggests many of the hurdles of Treg agonism may have been overcome. This review covers the current treatment landscape for MS, the basic science of TNFR2, the rationale for and evidence behind TNFR2 agonism to treat multiple sclerosis, the design of potent TNFR2 agonist antibodies, and the treatment applications for other neurological, autoimmune, or inflammatory diseases.<\/jats:p>","DOI":"10.3390\/ijms26167839","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:44:21Z","timestamp":1755186261000},"page":"7839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-4812","authenticated-orcid":false,"given":"Denise L.","family":"Faustman","sequence":"first","affiliation":[{"name":"Laboratory of Immunobiology, Massachusetts General Hospital, and Harvard Medical School, Room 3602, MGH-East, Bldg 149, 13th Street, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Davis","sequence":"additional","affiliation":[{"name":"Laboratory of Immunobiology, Massachusetts General Hospital, MGH-East, Bldg 149, 13th Street, Boston, MA 02129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M.","family":"Kuhtreiber","sequence":"additional","affiliation":[{"name":"Laboratory of Immunobiology, Massachusetts General Hospital, and Harvard Medical School, Room 3602, MGH-East, Bldg 149, 13th Street, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple Sclerosis Pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1523\/JNEUROSCI.0211-16.2016","article-title":"Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination","volume":"36","author":"Madsen","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1073\/pnas.1807499115","article-title":"Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity","volume":"115","author":"Atretkhany","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbi.2019.06.021","article-title":"Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis","volume":"81","author":"Fischer","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12974-023-02784-z","article-title":"Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis","volume":"20","author":"Fiedler","year":"2023","journal-title":"J. Neuroinflamm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: Drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Faustman, D.L., and Davis, M. (2013). TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00478"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of Multiple Sclerosis: A Review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mohammed, E.M.A. (2024). Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects. Front. Biosci., 29.","DOI":"10.31083\/j.fbl2911386"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","article-title":"Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting","volume":"186","author":"Charabati","year":"2023","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e230016","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: A systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11910-021-01110-5","article-title":"Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications","volume":"21","author":"Simkins","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Behrangi, N., Fischbach, F., and Kipp, M. (2019). Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells, 8.","DOI":"10.3390\/cells8010024"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/1352458520969105","article-title":"Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis","volume":"27","author":"Preziosa","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40120-022-00363-7","article-title":"A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis","volume":"11","author":"Collongues","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, J.H., Rempe, T., Whitmire, N., Dunn-Pirio, A., and Graves, J.S. (2022). Therapeutic Advances in Multiple Sclerosis. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.824926"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"578315","DOI":"10.1016\/j.jneuroim.2024.578315","article-title":"Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis","volume":"390","author":"Sriwastava","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: Time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Day","year":"2018","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis","volume":"43","author":"Sladowska","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.170.2.607","article-title":"Tumor necrosis factor identified in multiple sclerosis brain","volume":"170","author":"Hofman","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wajant, H., and Siegmund, D. (2019). TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00091"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1742-4658.2011.08017.x","article-title":"Tumor necrosis factor receptor cross-talk","volume":"278","author":"Naude","year":"2011","journal-title":"FEBS J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yang, S., Wang, J., Brand, D.D., and Zheng, S.G. (2018). Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00784"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1002\/eji.1830241139","article-title":"Involvement of the tumor necrosis factor receptor p75 in mediating cytotoxicity and gene regulating activities","volume":"24","author":"Medvedev","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.1995.15.171","article-title":"Upregulation of NF-kappa B-dependent gene expression mediated by the p75 tumor necrosis factor receptor","volume":"15","author":"Rao","year":"1995","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108823","DOI":"10.1016\/j.intimp.2022.108823","article-title":"Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4(+)Foxp3(+) regulatory T cells","volume":"108","author":"He","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","article-title":"Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4(+)CD25(+) T regulatory cells","volume":"179","author":"Chen","year":"2007","journal-title":"J. Immunol."},{"key":"ref_34","first-page":"8","article-title":"Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF","volume":"47","author":"Grell","year":"1995","journal-title":"J. Inflamm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jnr.20531","article-title":"Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro","volume":"80","author":"Cacci","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1750-3639.2008.00151.x","article-title":"Tumor necrosis factor alpha is reparative via TNFR2 [corrected] in the hippocampus and via TNFR1 [corrected] in the striatum after virus-induced encephalitis","volume":"19","author":"Rodriguez","year":"2009","journal-title":"Brain Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1093\/brain\/awr199","article-title":"Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination","volume":"134","author":"Brambilla","year":"2011","journal-title":"Brain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nn738","article-title":"TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination","volume":"4","author":"Arnett","year":"2001","journal-title":"Nat. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1023\/A:1021608724117","article-title":"Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells","volume":"27","author":"Dopp","year":"2002","journal-title":"Neurochem. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbi.2023.12.025","article-title":"Microglial TNFR2 signaling regulates the inflammatory response after CNS injury in a sex-specific fashion","volume":"116","author":"Raffaele","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbrc.2013.09.083","article-title":"TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress","volume":"440","author":"Maier","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bbi.2024.09.002","article-title":"TNFR2 signaling in oligodendrocyte precursor cells suppresses their immune-inflammatory function and detrimental microglia activation in CNS demyelinating disease","volume":"123","author":"Desu","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-5728(99)00083-1","article-title":"The origin of remyelinating cells in the central nervous system","volume":"98","author":"Blakemore","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5383099","DOI":"10.1155\/2024\/5383099","article-title":"The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis","volume":"2024","author":"Sarkar","year":"2024","journal-title":"J. Immunol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1352458518796693","article-title":"Astrocytes play a crucial role in the formation and evolution of MS lesions\u2014Commentary","volume":"25","author":"Quintana","year":"2019","journal-title":"Mult. Scler."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2014043118","DOI":"10.1073\/pnas.2014043118","article-title":"Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells","volume":"118","author":"Ronin","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e200251","DOI":"10.1212\/NXI.0000000000200251","article-title":"Alterations of Thymus-Derived Tregs in Multiple Sclerosis","volume":"11","author":"Lorenzini","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410230405","article-title":"Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro","volume":"23","author":"Selmaj","year":"1988","journal-title":"Ann. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF00916935","article-title":"In vitro study of mediators of inflammation in multiple sclerosis","volume":"9","author":"Merrill","year":"1989","journal-title":"J. Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"Barkhof","year":"1996","journal-title":"Neurology"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group (1999). TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology, 53, 457\u2013465.","DOI":"10.1212\/WNL.53.3.457"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A","article-title":"Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1","volume":"29","author":"Eugster","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/cimm.2000.1706","article-title":"Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis","volume":"205","author":"Suvannavejh","year":"2000","journal-title":"Cell Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"RC216","DOI":"10.1523\/JNEUROSCI.22-07-j0001.2002","article-title":"Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2","volume":"22","author":"Fontaine","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.celrep.2016.11.083","article-title":"Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis","volume":"18","author":"Gao","year":"2017","journal-title":"Cell Rep."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Williams, S.K., Maier, O., Fischer, R., Fairless, R., Hochmeister, S., Stojic, A., Pick, L., Haar, D., Musiol, S., and Storch, M.K. (2014). Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090117"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Williams, S.K., Fairless, R., Maier, O., Liermann, P.C., Pichi, K., Fischer, R., Eisel, U.L.M., Kontermann, R., Herrmann, A., and Weksler, B. (2018). Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-31957-7"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12974-023-02785-y","article-title":"Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS","volume":"20","author":"Pegoretti","year":"2023","journal-title":"J. Neuroinflamm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"110885","DOI":"10.1016\/j.brainresbull.2024.110885","article-title":"Tumor necrosis factor receptor 2 activation elicits sex-specific effects on cortical myelin proteins and functional recovery in a model of multiple sclerosis","volume":"207","author":"Nguyen","year":"2024","journal-title":"Brain Res. Bull."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-5-45","article-title":"TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease","volume":"5","author":"McCoy","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41584-023-01002-7","article-title":"TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond","volume":"19","author":"Siegmund","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., and Pfizenmaier, K. (2011). A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027621"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17045","DOI":"10.1073\/pnas.1902091116","article-title":"TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes","volume":"116","author":"Fischer","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/cns.13125","article-title":"Continuous infusion of an agonist of the tumor necrosis factor receptor 2 in the spinal cord improves recovery after traumatic contusive injury","volume":"25","author":"Gerald","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"578246","DOI":"10.1016\/j.jneuroim.2023.578246","article-title":"Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke","volume":"385","author":"Thougaard","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e2201137119","DOI":"10.1073\/pnas.2201137119","article-title":"A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer\u2019s disease mouse model","volume":"119","author":"Zuhorn","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3233\/JAD-221230","article-title":"Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-beta Clearance in an Alzheimer\u2019s Disease Mouse Model with Humanized TNF Receptor 2","volume":"94","author":"Wajant","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12974-021-02200-4","article-title":"Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKbeta promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice","volume":"18","author":"Papazian","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","article-title":"Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial","volume":"84","author":"Butchart","year":"2015","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40478-020-00957-y","article-title":"Characterization of the TNF and IL-1 systems in human brain and blood after ischemic stroke","volume":"8","author":"Clausen","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Leone, G.M., Mangano, K., Petralia, M.C., Nicoletti, F., and Fagone, P. (2023). Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041630"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101941","DOI":"10.1016\/j.berh.2024.101941","article-title":"TNFR2 signalling in inflammatory diseases","volume":"38","author":"Williams","year":"2024","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Okubo, Y., Mera, T., Wang, L., and Faustman, D.L. (2013). Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep., 3.","DOI":"10.1038\/srep03153"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/cti.2015.43","article-title":"Treg activation defect in type 1 diabetes: Correction with TNFR2 agonism","volume":"5","author":"Okubo","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"13644","DOI":"10.1073\/pnas.0803429105","article-title":"Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism","volume":"105","author":"Ban","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Vargas, J.G., Wagner, J., Shaikh, H., Lang, I., Medler, J., Anany, M., Steinfatt, T., Mosca, J.P., Haack, S., and Dahlhoff, J. (2022). A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.888274"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1084\/jem.20151563","article-title":"Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion","volume":"213","author":"Chopra","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2016-02-700849","article-title":"Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells","volume":"128","author":"Leclerc","year":"2016","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.gastro.2015.06.004","article-title":"Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis","volume":"149","author":"Punit","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Chen, X., Nie, Y., Xiao, H., Bian, Z., Scarzello, A.J., Song, N.Y., Trivett, A.L., Yang, D., and Oppenheim, J.J. (2016). Corrigendum: TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. Sci. Rep., 6.","DOI":"10.1038\/srep34680"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Candel, S., de Oliveira, S., Lopez-Munoz, A., Garcia-Moreno, D., Espin-Palazon, R., Tyrkalska, S.D., Cayuela, M.L., Renshaw, S.A., Corbalan-Velez, R., and Vidal-Abarca, I. (2014). Tnfa signaling through tnfr2 protects skin against oxidative stress-induced inflammation. PLoS Biol., 12.","DOI":"10.1371\/journal.pbio.1001855"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/JLB.2MA0121-082R","article-title":"Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis","volume":"110","author":"Chen","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kaur, R., Harvey, J.M., Brambilla, R., Chandrasekharan, U.M., and Elaine Husni, M. (2024). Targeting dendritic cell-specific TNFR2 improves skin and joint inflammation by inhibiting IL-12\/IFN-gamma pathways in a mouse model of psoriatic arthritis. bioRxiv, bioRxiv:2024.06.20.598545.","DOI":"10.1101\/2024.06.20.598545"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.40413","article-title":"Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis","volume":"70","author":"Fischer","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"21666","DOI":"10.1073\/pnas.1909687116","article-title":"TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells","volume":"116","author":"Tseng","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Pesce, B., Ribeiro, C.H., Larrondo, M., Ramos, V., Soto, L., Catalan, D., and Aguillon, J.C. (2022). TNF-alpha Affects Signature Cytokines of Th1 and Th17 T Cell Subsets through Differential Actions on TNFR1 and TNFR2. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169306"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1093\/rheumatology\/keac124","article-title":"TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation","volume":"61","author":"Suto","year":"2022","journal-title":"Rheumatology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:58Z","timestamp":1760034418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":90,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26167839"],"URL":"https:\/\/doi.org\/10.3390\/ijms26167839","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}